Non Corticosteroid Immunomodulators Market

Market Overview

The primary types of non-corticosteroid immunomodulators include, calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, and IMDH inhibitors among other drug classes. Cyclosporine and tacrolimus are two of the calcineurin inhibitors that are approved by the FDA for the treatment of atopic dermatitis. Antiproliferative agents are also called antimetabolites, this is a drug class that inhibits the cell-cycle pathways to limit T- and B-cell proliferation to reduce the cytotoxic response directed toward an organ transplant such as cardiac allograft. The drug class mTOR inhibitors, inhibits the mammalian target of rapamycin (mTOR), that is particularly of interest for treatment of renal diseases.

IMDH inhibitor is also an immunosuppressant that inhibits the enzyme inosine monophosphate dehydrogenase (IMDH). The IMDH is known to play an important role in the regulation of cell-cell contacts. Thus the drug class is used to suppress the immune system during organ transplant recovery. A majority of the non-corticosteroids are immunosuppressant in nature. These products are either prescribed along with corticosteroids or as stand-alone therapies based on the condition of the patient.

Increase in number of organ transplantation is one of the factors that drives the growth of non-corticosteroid immunomodulators market. Rise in FDA approvals for biologics and increase in number of biologic manufacturers in countries like China and India is also expected to drive the growth of the non-corticosteroid immunomodulators market globally. Rising prevalence of diseases such as atopic dermatitis and inflammatory bowel disease offer a rising pool of patients that will increase the demand for non-corticosteroid immunomodulators market. However, high cost of manufacturing, rising pricing pressure, poor reimbursement in developing nations are some of the factors that will inhibit the growth of the non-corticosteroid immunomodulators market. 

Market Segmentation

Key Players

The Non-corticosteroid Immunomodulators market includes some key players such as Accord Healthcare, Bristol-Myers Squibb Company, Astella Pharma, Genzyme Co., GlaxoSmithKline PLC, Merck KGaA, F. Hoffmann-La Roche AG, Glenmark Pharmaceuticals, Inc., Pfizer Inc., Mylan Laboratories Inc., Actavis, Inc., Novartis AG, and Zydus Cadila among others. Launch of new products is the basic strategy of most key players in the non-corticosteroid immunomodulators market. Most companies are focused towards investing in R&D to develop and launch new innovative products. A number of non-corticosteroid immunomodulators are in pipeline and are expected to launch soon. This will further dive the growth of the non-corticosteroid immunomodulators market during the forecast period.

The report covers exhaustive analysis on:

• Non-corticosteroid Immunomodulators Market Segments
• Non-corticosteroid Immunomodulators Market  Dynamics
• Historical Actual Non-corticosteroid Immunomodulators Market Size, 2014 - 2018
• Non-corticosteroid Immunomodulators Market  Size & Forecast 2018 to 2029
• Non-corticosteroid Immunomodulators Market  Current Trends/Issues/Challenges
• Competition & Companies involved
• Non-corticosteroid Immunomodulators Market Drivers and Restraints

Regional analysis includes

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size Recent industry trends
• Key Competition landscape
• Strategies of key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance